EFA receives funding from three sources: membership fees, public EU grants and corporate unrestricted grants. We are proud of the funding partnerships we have established. Funding received by EFA is transparent and accountable, and is based on independence and trust.
All EFA corporate sponsors sign up for EFA’s Sustainable Corporate Partnership Framework and provide support to EFA through core and project grants. Our relationship with EFA sustainable funding partners is ran in respect of our Code of Ethics and Conduct.
EU public funding is granted to EFA to participate in EU projects from funding programmes from the European Commission.
EFA acknowledges the contribution of the following funders to our core and project programmes 2023: AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Sanofi Genzyme, Regeneron, AbbVie, Roche, OM Pharma, Pfizer, Viatris, DBV Technologies.
EFA funding is transparent
Every funding source received by EFA is scrutinised and listed in our Annual Reports, including the latest 2023 Annual Report.
Funding to EFA supports our allergy and airways information, care and prevention programmes. Programmes are designed to respond to the needs of patients and member associations through the unique position EFA has at the European level. EFA unifies national patient groups and represents them at the European level. Programmes are decided by the EFA board and Annual General Meeting of members, the European allergy and airways patient community.
If you have questions about EFA funding and how it is managed, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.
Accountability of funding is an everyday job at EFA
Funding supports the allergy and airways information, care and prevention programme. Programmes arise from needs of patients and the unique position EFA has at the European level. EFA unifies national patient groups and represents them at the European level. Programmes are decided by the EFA board and the Annual General Meeting (AGM) of members, and the European allergy and airways patient community.
EFA Board ensures good governance
Funds are managed following the principles of good governance. Our Annual Reports, audited financial accounts and overall budget for the next year is approved by the Annual General Meeting of Members.
- EFA Board reviews Quarterly reports, based on a budget approved by the AGM and a Balance Sheet.
- Financial Accounts are audited by a certified Auditor.
- EFA Board reports to the Annual General Meeting of Members for their approval of accounts.
EFA delivers according to our multiannual strategy and annual plans and follows a strict expenditure policy. EFA is a non-for-profit organisation, but we have responsible social and organisational reserve.
Become EFA funding partner, you will not regret it!
We are proud of our sustainable corporate partnerships with our funders. As partners, corporate, non-profit and public structures help us to advocate change for allergy and airways diseases patients in Europe and to inform, prevent and care for these diseases from a patient perspective.
Thank you to EFA funders!
If you wish to become an EFA funding partner please contact This email address is being protected from spambots. You need JavaScript enabled to view it..
Thank you to EFA funders
EFA acknowledges the contribution of the following funders to our core and project programmes 2023: AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Sanofi Genzyme, Regeneron, AbbVie, Roche, OM Pharma, Pfizer, Viatris, DBV Technologies.
EFA Annual Reports
Our 2023 Annual Report, including audited financial accounts and overall budget for the next year is approved by the Annual General Meeting of Members.
Here are the reports from 2022, 2021, 2020, 2019, 2018, 2017, 2016, 2015, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007, 2006 and 2005.